Equities analysts expect that Medgenics Inc (NASDAQ:GNMX) will report earnings of ($0.26) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Medgenics’ earnings. The lowest EPS estimate is ($0.32) and the highest is ($0.17). Medgenics posted earnings per share of ($0.35) during the same quarter last year, which would indicate a positive year over year growth rate of 25.7%. The firm is scheduled to announce its next quarterly earnings report on Thursday, August 3rd.
On average, analysts expect that Medgenics will report full-year earnings of ($1.11) per share for the current financial year, with EPS estimates ranging from ($1.29) to ($0.88). For the next financial year, analysts expect that the company will report earnings of ($1.44) per share, with EPS estimates ranging from ($1.85) to ($1.04). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Medgenics.
Medgenics (NASDAQ:GNMX) last issued its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by $0.02.
GNMX has been the topic of several recent research reports. Needham & Company LLC restated a “buy” rating and set a $9.00 target price (down from $12.00) on shares of Medgenics in a report on Tuesday, March 21st. Jefferies Group LLC restated a “hold” rating and set a $1.50 target price on shares of Medgenics in a report on Friday, May 12th.
In other Medgenics news, Director Sol J. Barer acquired 100,000 shares of the company’s stock in a transaction dated Friday, April 28th. The shares were acquired at an average cost of $1.57 per share, for a total transaction of $157,000.00. Following the completion of the purchase, the director now owns 607,000 shares of the company’s stock, valued at approximately $952,990. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Philip R. Harper acquired 1,058,531 shares of the company’s stock in a transaction dated Friday, March 24th. The stock was acquired at an average price of $1.78 per share, for a total transaction of $1,884,185.18. Following the completion of the purchase, the insider now directly owns 4,786,682 shares of the company’s stock, valued at approximately $8,520,293.96. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 1,258,531 shares of company stock worth $2,195,185. Corporate insiders own 23.40% of the company’s stock.
Several institutional investors have recently bought and sold shares of GNMX. Birchview Capital LP raised its position in Medgenics by 41.7% in the first quarter. Birchview Capital LP now owns 68,000 shares of the biotechnology company’s stock worth $126,000 after buying an additional 20,000 shares during the last quarter. Massey Quick & Co. LLC acquired a new position in Medgenics during the fourth quarter worth approximately $126,000. TIAA CREF Investment Management LLC raised its position in Medgenics by 16.7% in the first quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock worth $182,000 after buying an additional 13,966 shares during the last quarter. Teachers Advisors LLC acquired a new position in Medgenics during the fourth quarter worth approximately $204,000. Finally, Oxford Asset Management acquired a new position in Medgenics during the fourth quarter worth approximately $249,000. Institutional investors and hedge funds own 44.69% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Mideast Time and is owned by of Mideast Time. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.mideasttime.com/medgenics-inc-gnmx-expected-to-post-earnings-of-0-26-per-share/1708636.html.
Shares of Medgenics (NASDAQ:GNMX) traded up 1.56% during midday trading on Tuesday, hitting $1.30. The stock had a trading volume of 298,748 shares. The firm’s market cap is $48.24 million. Medgenics has a 1-year low of $1.26 and a 1-year high of $6.89. The firm has a 50-day moving average price of $1.61 and a 200-day moving average price of $4.04.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medgenics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics Inc and related companies with MarketBeat.com's FREE daily email newsletter.